Ekso Bionics Holdings (NASDAQ:EKSO) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.35) by 8.15 percent. This is a 36.41 percent increase over losses of $(1.95) per share from the same period last year. The company reported quarterly sales of $2.100 million which missed the analyst consensus estimate of $4.313 million by 51.30 percent. This is a 57.58 percent decrease over sales of $4.950 million the same period last year.